Eyal C. Attar
CIK 1789076 · View on SEC EDGAR ↗
First SEC filing: Oct. 2, 2019 · Latest: Oct. 2, 2019
On this page
- Insider at Companies where this person is a reporting insider.
- Insider transactions Every share this person bought or sold, from Form 4 filings.
- Derivatives Options and other derivative holdings reported by this person.
- Initial holdings The stakes this person held when they first started reporting.
- Compensation Executive pay disclosed in company proxy statements.
Insider at
Insider transactions
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| June 3, 2024 | VOR | S 10b5-1 | 14,645 | $1.39 | $20,357 | 96,063 Direct | -13.23% | Disposed | -17.6% (price as of 2026-08-20) |
| Feb. 28, 2022 | APRE | S 10b5-1 | 36,000 | $1.73 | $62,280 | 47,000 Direct | -43.37% | Disposed | -98.1% (price as of 2026-08-20) |
| Sept. 16, 2021 | APRE | S 10b5-1 | 15,968 | $4.68 | $74,730 | 83,000 Direct | -16.13% | Disposed | -99.3% (price as of 2026-08-20) |
| Oct. 7, 2019 | APRE | P | 200 | $15.00 | $3,000 | 200 Indirect | — | Acquired | -99.8% (price as of 2026-08-20) |
| Oct. 7, 2019 | APRE | P | 200 | $15.00 | $3,000 | 200 Indirect | — | Acquired | -99.8% (price as of 2026-08-20) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II)
Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| Jan. 29, 2024 | VOR | Employee Stock Option (right to buy) | Common Stock (125,000) | $2.41 | Jan. 28, 2034 | 125,000 | Acquired |
| Feb. 6, 2023 | VOR | Employee Stock Option (right to buy) | Common Stock (109,000) | $5.55 | Feb. 5, 2033 | 109,000 | Acquired |
| Oct. 11, 2022 | VOR | Employee Stock Option (right to buy) | Common Stock (364,000) | $3.77 | Oct. 10, 2032 | 364,000 | Acquired |
| March 10, 2022 | APRE | Stock Option (right to Buy) | Common Stock (185,900) | $1.82 | March 10, 2032 | 185,900 | Acquired |
| Feb. 25, 2021 | APRE | Stock Option (right to Buy) | Common Stock (143,000) | $6.00 | Feb. 25, 2031 | 143,000 | Acquired |
| March 24, 2020 | APRE | Stock Option (right to Buy) | Common Stock (55,000) | $35.50 | March 24, 2030 | 55,000 | Acquired |
| Oct. 7, 2019 | APRE | Stock Option (right to Buy) | Common Stock (77,630) | $15.00 | Oct. 2, 2029 | 77,630 | Acquired |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Initial ownership (Form 3) 1 holding
Securities held when first becoming an insider, per SEC Form 3.
| Date | Ticker | Security | Shares | Ownership |
|---|---|---|---|---|
| Oct. 2, 2019 | APRE | Stock Option (right to buy)→ Common Stock (262,736) | 262,736 | Direct |
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2019 | $301,250 | — | — | $766,208 | $121,825 | — | — | $1,189,283 |
VOR
M.D.(7) Former Chief Medical Officer| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2024 | $487,100 | — | $150,625 | $230,000 | $195,303 | — | $12,757 | $1,075,785 |
| 2023 | $474,000 | — | — | — | $180,286 | — | $6,269 | $1,400,120 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.